Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Meridian Bioscience’s Illumigene group A Streptococcus and group B Streptococcus tests have been recategorized under CLIA as moderate complexity. The new categorization of these tests allows the Illumigene platform to be available to all moderate-complexity labs in U.S. hospitals and clinics, allowing them to offer an accurate, rapid, simple molecular test for each of these pathogens.
Audit MicroControls’ MicroFD urine chemistry control, two levels, is intended to simulate human patient samples for monitoring the precision of laboratory testing procedures for urine chemistry assays, including amylase, calcium, chloride, creatinine, glucose, magnesium, microalbumin, microprotein, phosphorous, potassium, sodium, urea nitrogen, and uric acid.
Quest Diagnostics offers a clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
Randox Laboratories’ www.riqas.com allows users to discover the benefits offered by the Randox International Quality Assessment Scheme (RIQAS) and the advantages of implementing external quality assessment (EQA). The Web site displays information on well-designed, easy-to-navigate pages.
Bio/Data Corp.’s Collagen synthetic reactive peptide (SRP) is a synthetic type-1 collagen-like liquid polypeptide that self-assembles into a helix to form fibrils. Synthetic collagen may be useful in laboratories investigating platelet function and reactivity, platelet activation, and cellular analysis.
Qiagen offers a sample-to-result next-gen sequencing workflow designed to enable the routine use of NGS technology in areas such as clinical research and diagnostics. Qiagen’s NGS workflow is an ecosystem of products and services that offer automated processes from primary sample to digital result.
Eppendorf North America’s µCuvette G1.0 is for measuring small volumes of highly concentrated biomolecules, such as proteins and nucleic acids. Users can work easily with samples as small as 1.5 μL, without the need for a time-consuming dilution step. The μCuvette G1.0 expands the measuring range of the Eppendorf BioPhotometer and BioSpectrometer.
Roche has received FDA approval for its Cobas AmpliPrep/Cobas TaqMan HCV test, v2.0. The next-generation viral load test is for use in the management of patients with chronic hepatitis C virus infection. The test provides a novel dual-probe approach, for an extra layer of protection in detecting and quantifying the virus and is designed to accurately determine the amount of HCV RNA to assess a patient’s response to antiviral therapy.
Agilent Technologies’ SureSelect strand-specific RNA library preparation kit for whole transcriptome and targeted RNA sequencing allows researchers to prepare high-quality, strand-specific libraries for next-generation sequencing. The ability to gain strand-specific information from RNA sequencing experiments allows researchers to more easily discern overlapping transcripts and investigate antisense expression to better understand gene regulation.
Cerilliant offers certified spiking solutions for use in preparing T4-13C6, T3-13C6, and reverse T3-13C6 calibrators and controls for monitoring free and total thyroid hormone levels in serum or plasma by liquid chromatography-tandem mass spectrometry. These products offer clinical and endocrinology labs the full range of stable-labeled internal standards necessary for accurate quantitation of T4, T3, and reverse T3, using LC-MS/MS.
